Havn Life Sciences Inc · CSE:HAVN
Havn Life Sciences — Investor Presentation (January 2021)
19 slides from Havn Life Sciences's investor presentation, January 2021
Slide 1: The Future of Psychedelic Therapy
The Future of Psychedelic Therapy CSE: HAVN | FRA: 5NP
Slide 2: Investment Highlights
INVESTMENT HIGHLIGHTS HAVN Life is focused on the rapidly growing field of psychedelic medicine. We have the opportunity to lead the standardization of psychedelic supply to shift human performance and mental health paradigms. DEFINED ROUTE TO NATURAL HEALTH PRODUCTS MARKET. DEVELOPING STATE-OF-THE-
Slide 3: Mission
MISSION Our mission is to unlock human performance using evidence-informed research. We are focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds. Investor Deck 2021 3
Slide 4: Core Pillars
CORE PILLARS HAVN Labs HAVN Retail A GMP laboratory that will be dedicated HAVN Life will be developing custom to growing and developing extraction formulations that will deliver natural health methodology of psychoactive and products with increased bioavailability to psychedelic compounds. support
Slide 5: Our Story
O U R STO RY HAVN Life is a part of a global community Through end to end research, extraction, taking an active part in supporting formulation and delivery, we aspire to research for microdosing therapies in define and standardize the future of treating mental health disorders utilizing modern medi
Slide 6: Collaboration Across Disciplines
C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S Creating positive patient experience and mental health outcomes Vic Neufeld Tim Moore Gary Leong Executive Chairman Chief Executive Officer Chief Scientific Officer • CEO of Aphria for 5 years during large scale • Former CEO of Green Growth B
Slide 7: Collaboration Across Disciplines
C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S Dr. Ivan Casselman Alexzander Samuelsson Eli Dusenbury Juliana Mollica Chief Psychedelic Officer Chief Research Officer Chief Financial Officer Director of Innovation and • Extensive nutraceutical formulation • Lead chemist of a publicly trad
Slide 8: Collaboration Across Disciplines
C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S Rick Brar Tim Laidler Barinder Rasode Vice Chairman Director President • Mr.Brar is the CEO & Chairman of Brains • Tim completed a Master of Counselling at • Served two terms as elected Councilor for Bioceutical Corp. A global manufacturer an
Slide 9: Collaboration Across Disciplines
C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S Sheila Copps Allan Oberman David Mokler Advisor Advisor Advisor • The Honourable Sheila Copps was the first • Mr. Oberman served as CEO for Concordia • Dr. David Mokler neuropharmacology, woman to ever hold the position of Deputy Internationl
Slide 10: Path to Market
PAT H T O M A R K E T UNREGULATED ROUTE REGULATED ROUTE TO MARKET TO MARKET Natural Health Psychedelic Products Extraction and Supply Direct to Contract Supply Academic Formulate Microdosing Consumers Manufacturer Research Therapies (White Label) (Dealers License) (Pre-Clinical Trials) Investor Deck
Slide 11: State-of-the-art Mycology Laboratory
State-of-the-art A lab devoted to the Facility advancement and Mycology formulation of regulated Laboratory and novel psychoactive compounds. Formulation Capabilities Investor Deck 2021 11
Slide 12: State-of-the-Art Facility
STATE-OF-THE-ART FACILITY HAVN Labs operates from a state-of-the-art research facility located in the South Campus at The University of British Columbia. MYCOLOGY LABORATORY With the ability to expand into a pilot plant in the same facility. Able to formulate and manufacture in one location. FORMULA
Slide 13: HAVN Labs work with veterans and PTSD groups
HAVN Labs will work with veterans and PTSD groups across North America to develop strategic evidence based treatment protocols and optimize formulations to study mental well being. Currently global access to research informed formulations is limited. Those who are studying psychedelics in research s
Slide 14: Roadmap
ROA D M A P Finalize Pre-Clinical Manufacture & Distribute Expansion of Distribution Protocols for at Scale Channels R E TA I L Compound Extraction Licensed Dealer and Supply Approval 2020 2021 2022+ Supply Clinical Trials with Formulate Received first GMP Certified Natural Publish Analytical LABS P
Slide 15: Comparables
C O M PA R A B L E S Attractive Valuation Relative to Peer Group Drug Development & Microdosing/Consumer Brand & Operational Focus Clinical Research Clinical Wellness Clinics Research & Clinics Clinical Research Market Segment Health & Wellness Medicinal Research Health & Wellness Medicinal Public o
Slide 16: Growing Mushroom Market
G ROWING M USHROOM MARKET Global Revenue in 2016 - 2024 40B 35B The global functional food market is expected to reach $34.3 Billion USD by $34.292 30B Billions $USD 2024, registering a CAGR of 8.04% during $31.717 25B $29.346 the forecast period (2019-2024). $27.161 $25.147 20B $23.290 The market s
Slide 17: Capitalization
C A P I TA L I Z AT I O N Shares Total Issued & Outstanding 66,971,000 Warrants & Options 21,715,000 Fully Diluted 88,686,000 Notes • 15.5m Management Escrow over 36 Months • 16,474,000 shares via pre-IPO financing at CDN $0.25 restricted until January 10, 2021 • In addition to Issued & Oustanding,
Slide 18: Disclaimer
DISCLAIMER This presentation is confidential and is being issued by HAVN Life (the “Company”) for informational purposes only. Reliance on frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,” this presentation for the purp
Slide 19: Thank You
THANK YOU IR@HAVN LIFE.COM CSE: HAVN | FRA: 5NP Investor Deck 19
HAVN Life Sciences — Investor Presentation (January 2021) on 6ix